Delescluse J, Cauwenbergh G, Degreef H
Br J Dermatol. 1986 Jun;114(6):701-3. doi: 10.1111/j.1365-2133.1986.tb04879.x.
Itraconazole, a new orally active triazole antifungal, has been tested in patients with pityriasis versicolor. A comparison of different dose schedules was carried out in 73 patients. A regime of 100 mg itraconazole daily for 15 days gave a 100% response rate; 200 mg daily for 5 days gave an 80% response rate. Two patients, who had received 50 mg itraconazole for 14 days, relapsed within 2 months of finishing treatment. Only two patients reported minor side-effects.
伊曲康唑是一种新型口服活性三唑类抗真菌药，已在花斑癣患者中进行了试验。对73例患者进行了不同给药方案的比较。每天服用100毫克伊曲康唑，持续15天的方案有效率为100%；每天服用200毫克，持续5天的方案有效率为80%。两名接受50毫克伊曲康唑治疗14天的患者在完成治疗后2个月内复发。只有两名患者报告有轻微副作用。
